A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 47/48 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2193092
The invention relates to antibodies to T cells as therapeutics. The object underlying the invention is to provide antibodies for a clinical therapy for prolonging the immunosuppressive antibody effect while avoiding the formation of antiantibodies. This object is achieved by providing antibodies consisting of at least two different groups which are applied at different times and in which at least one antibody of group B differs from one antibody of group A in the constant regions of its heavy chains and wherein group A, which is first applied once or several times, has a T- cell eliminating effect, while the other group B (which is applied at a different time) has a T-cell eliminating and/or T-cell antigen modulating effect.
L'invention vise à préparer des anticorps pour une thérapie clinique, qui permettent de prolonger l'effet immunosuppresseur des anticorps, tout en évitant la formation d'anti-anticorps. A cet effet, on utilise des anticorps qui comprennent au moins deux groupes différents qui sont administrés séparément dans le temps et dans lesquels au moins un anticorps du groupe B se distingue, dans les parties constantes des chaînes lourdes, d'un anticorps du groupe A, et où le groupe A qui est appliqué le premier une ou plusieurs fois, possède une action éliminatrice des cellules T, alors que le groupe B (qui est appliqué après un intervalle de temps) possède une action éliminatrice des cellules T et/ou une action modulatrice de l'antigène des cellules T.
Blake Cassels & Graydon Llp
Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh
LandOfFree
Antibodies against t cells as therapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against t cells as therapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against t cells as therapeutics will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1728116